SONY

Product Data Sheet

APC/Fire™ 750 anti-human HLA-DR

Catalog # / Size:	2235120 / 100 tests 2235115 / 25 tests
Clone:	LN3
Isotype:	Mouse IgG2b, κ
Immunogen:	human PBL
Reactivity:	Human, Other
Preparation:	The antibody was purified by affinity chromatography and conjugated with APC/Fire™ 750 under optimal conditions.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Workshop Number:	750 under optimal conditions.
Concentration:	Lot-specific



Human peripheral blood lymphocytes were stained with HLA-DR (clone LN3) APC/Fire™ 750 (filled histogram) or mouse IgG2b, κ APC/Fire™ 750 isotype control (open histogram).

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. * APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.
Application Notes:	Additional reported applications (for the relevant formats) include: immunohistochemical staining[1] of frozen sections and formalin-fixed paraffin-embedded sections[1], and immunoprecipitation[1].



Application References:

1. Marder RJ, *et al.* 1985. *Lab. Invest.* 52:497.
2. Norton AJ and Isaacson PG. 1987. *Am. J. Pathol.* 128:225.
3. Hua ZX, *et al.* 1998. *Hum. Pathol.* 29(12):1441.

Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

Description: The LN3 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to $CD4^+$ T cells.

Antigen References:

1. Levacher M, *et al.* 1990. *Clin. Exp. Immunol.* 81:177.
2. Terstappen L, *et al.* 1990. *J. Leuk. Biol.* 48:138.
3. Edwards J, *et al.* 1985. *J. Immunol.* 137:490.
4. van Es A, *et al.* 1984. *Transplantation* 37:65.
5. O'Doherty U, *et al.* 1994. *Immunology* 82:487.
6. Thomas R, *et al.* 1994. *J. Immunol.* 153:4016.
7. Grouard G, *et al.* 1996. *Nature* 384:364.